Table S7. Prognostic effect of the copy number of genomic regions. Univariate results in optimal quality samples only.
| Chr | Region ID | CNA frequency | Disease-free survival | Overall survival | Lung-cancer specific survival | Mb | Genes | cytoBands | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Losses | Gains | HR for loss* (95% CI) | HR for gain** (95% CI) | P | Q | HR for loss* (95% CI) | HR for gain** (95% CI) | P | Q | HR for loss* (95% CI) | HR for gain** (95% CI) | P | Q | ||||||||
| 3 | 71 | 2.1% | 34.0% | 1.8 (1.2–2.6) | 0.56 (0.39–0.81) | 0.002 | 0.096 | 3.0E−2 | q26.1 | ||||||||||||
| 72 | 2.1% | 34.7% | 1.8 (1.2–2.6) | 0.57 (0.39–0.83) | 0.004 | 0.164 | 2.1 (1.4–3.1) | 0.48 (0.32–0.73) | <0.001 | 0.096 | 1.9 (1.2–2.8) | 0.54 (0.35–0.81) | 0.003 | 0.123 | 5.0E+0 | MECOM | q26.1–2 | ||||
| 9 | 210 | 29.0% | 3.6% | 2.3 (1.4–3.7) | 0.44 (0.27–0.72) | 0.001 | 0.077 | 2.2 (1.3–3.8) | 0.45 (0.27–0.76) | 0.003 | 0.107 | 2.6 (1.5–4.3) | 0.39 (0.23–0.66) | <0.001 | 0.051 | 5.0E+0 | MLLT3 | p22.3–p21.3 | |||
| 211 | 34.8% | 3.4% | 1.9 (1.4–2.7) | 0.52 (0.37–0.72) | <0.001 | 0.053 | 2.0 (1.4–2.9) | 0.50 (0.34–0.72) | <0.001 | 0.075 | 2.1 (1.5–3) | 0.48 (0.33–0.68) | <0.001 | 0.016 | 3.0E−1 | p21.3 | |||||
| 212 | 35.9% | 3.3% | 1.6 (1.2–2.2) | 0.62 (0.45–0.85) | 0.003 | 0.147 | 1.7 (1.2–2.4) | 0.57 (0.41–0.81) | 0.001 | 0.096 | 1.7 (1.2–2.4) | 0.59 (0.42–0.83) | 0.002 | 0.100 | 6.0E−1 | p21.3 | |||||
| 213 | 38.7% | 3.2% | 1.5 (1.1–2) | 0.67 (0.5–0.88) | 0.004 | 0.164 | 1.6 (1.2–2.1) | 0.64 (0.47–0.86) | 0.003 | 0.123 | 6.0E−2 | p21.3 | |||||||||
| 214 | 40.2% | 3.0% | 1.5 (1.2–1.9) | 0.66 (0.52–0.84) | <0.001 | 0.077 | 1.5 (1.2–2.0) | 0.65 (0.50–0.84) | 0.001 | 0.066 | 3.0E−1 | CDKN2A, CDKN2B | p21.3 | ||||||||
| 215 | 36.3% | 3.3% | 1.7 (1.2–2.2) | 0.61 (0.45–0.82) | 0.001 | 0.077 | 1.7 (1.2–2.4) | 0.59 (0.42–0.81) | 0.001 | 0.096 | 1.7 (1.3–2.4) | 0.58 (0.42–0.80) | <0.001 | 0.058 | 2.0E+0 | p21.3 | |||||
| 217 | 35.0% | 3.9% | 1.7 (1.3–2.4) | 0.58 (0.42–0.79) | <0.001 | 0.077 | 1.9 (1.4–2.7) | 0.52 (0.38–0.73) | <0.001 | 0.027 | 9.0E−3 | p21.3 | |||||||||
| 218 | 32.8% | 4.5% | 1.7 (1.2–2.3) | 0.60 (0.43–0.83) | 0.002 | 0.136 | 1.7 (1.2–2.4) | 0.59 (0.41–0.85) | 0.004 | 0.133 | 1.8 (1.3–2.6) | 0.54 (0.38–0.77) | <0.001 | 0.051 | 5.0E−1 | p21.3 | |||||
| 219 | 30.5% | 4.6% | 2.0 (1.3–3.0) | 0.51 (0.34–0.76) | 0.001 | 0.077 | 2.0 (1.3–3.1) | 0.49 (0.32–0.77) | 0.002 | 0.096 | 2.1 (1.4–3.3) | 0.47 (0.3–0.73) | <0.001 | 0.051 | 2.0E+0 | p21.3–2 | |||||
| 220 | 30.1% | 4.8% | 1.6 (1.2–2.2) | 0.63 (0.46–0.86) | 0.004 | 0.133 | 2.0E−2 | p21.2 | |||||||||||||
| 222 | 27.8% | 5.2% | 2.1 (1.3–3.3) | 0.48 (0.30–0.77) | 0.002 | 0.096 | 2.0E+0 | p21.1 | |||||||||||||
| 223 | 26.0% | 6.4% | 1.9 (1.2–2.9) | 0.53 (0.35–0.82) | 0.004 | 0.164 | 2.1 (1.3–3.3) | 0.48 (0.3–0.77) | 0.002 | 0.096 | 7.0E−1 | p21.1 | |||||||||
| 19 | 383 | 8.0% | 2.5% | 2.5 (1.3–4.6) | 0.41 (0.22–0.76) | 0.005 | 0.164 | 2.8 (1.4–5.3) | 0.36 (0.19–0.7) | 0.003 | 0.103 | 4.0E+0 | p12–p11 | ||||||||
| 386 | 4.6% | 7.3% | 2.2 (1.3–3.9) | 0.45 (0.26–0.79) | 0.005 | 0.161 | 3.0E−1 | q11 | |||||||||||||
Results from a model adjuster by treatment arm, patient age, sex, performance status (PS), histology, T, and N stage. *, hazard ratio for a 2-fold lower copy number; **, hazard ratio for a 2-fold higher copy number.